A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors

Exclusion Criteria

• •1. Pregnancy, lactation, or breastfeeding.
• •2. Known hypersensitivity to any of the components of RO7296682, including but not limited to hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies.
• •3. History or clinical evidence of central nervous system (CNS) primary tumors or metastases.
• •4. Participants with another invasive malignancy in the last two years.
• •5. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
• •6. Participants with known active or uncontrolled infection.
• •7. Positive human immunodeficiency virus (HIV) test at screening.
• •8. Positive for Hepatitis B and C.
• •9. Vaccination with live vaccines within 28 days prior to C1D1.
• •10. Major surgical procedure or significant traumatic injury within 28 days prior to first RO7296682 infusion.
• •11. Participants with wound healing complications.
• •12. Dementia or altered mental status that would prohibit informed consent.
• •13. History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS (drug rash with eosinophilia and systemic symptoms).
• •14. Active or history of autoimmune disease or immune deficiency.
• •15. Prior treatment with checkpoint inhibitors (CPIs) (e.g. anti-CTLA4, anti-PD1, anti-PDL1), immunomodulatory monoclonal antibodies (mAbs) and/or mAb-derived therapies (approved or investigational) is approved.
• •16. Prior treatment with a CC chemokine receptor 4 (CCR4)-targeting (e.g. mogamulizumab) or a CD25-targeting agent (e.g. basiliximab) is prohibited.
• •17. Treatment with standard radiotherapy, any chemotherapeutic agent, targeted therapy or treatment with any other investigational drug (defined as treatment for which there is currently no regulatory authority-approved indication) within 28 days or 5 half-lives of the drug (whichever is shorter), prior to the first RO7296882 administration on C1D1.
• •18. Radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy (for which no wash out period is required).